07:18 AM EDT, 08/27/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday it has initiated a phase 3 clinical trial to evaluate bomedemstat, an investigational LSD1 inhibitor, for treating essential thrombocythemia in patients who have not previously received cytoreductive therapy.

The trial, which is enrolling around 300 patients, will compare bomedemstat to the standard chemotherapy treatment, hydroxyurea.

The primary endpoint is the durable clinicohematologic response rate, with key secondary endpoints assessing fatigue and overall symptoms.

Price: 116.54, Change: +0.27, Percent Change: +0.23